Drug intelligence / Profile preview

OvaTure

Development stage: Discontinued
Lead developer: Tempest Therapeutics
Modality: Cell Therapies

Overview

OvaTure was a preclinical cell-based fertility treatment developed by OvaScience, initially in collaboration with Intrexon. The treatment aimed to mature a woman's own egg precursor cells into fertilizable oocytes to address infertility. The underlying science for OvaTure was considered unproven and controversial. OvaScience terminated its exclusive collaboration agreement with Intrexon for OvaTure in May 2018, intending to pursue its development internally or with other partners, but its development for fertility treatment was ultimately terminated.

Beyond the preview

Go deeper on OvaTure.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OvaTure.

Explore the full profile